Cargando…

Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial

BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, predominantly affecting joints, which is initially treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). In RA patients with insufficient response to csDMARDs, the addition of predniso...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Leeuw, Matthijs S., Welsing, Paco M. J., de Hair, Maria J. H., Jacobs, Johannes W. G., Marijnissen, Anne C. A., Linn-Rasker, Suzanne P., Fodili, Faouzia, Bos, Reinhard, Tekstra, Janneke, van Laar, Jacob M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133012/ https://www.ncbi.nlm.nih.gov/pubmed/32248829 http://dx.doi.org/10.1186/s13063-020-04260-y

Ejemplares similares

Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients
por: van der Leeuw, Matthijs S., et al.
Publicado: (2023)

Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022)

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate
por: Verhoeven, Maxime M A, et al.
Publicado: (2020)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
por: Messelink, Marianne A., et al.
Publicado: (2022)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
por: van der Leeuw, Matthijs S., et al.
Publicado: (2022)

Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study
por: Verhoeven, Maxime M A, et al.
Publicado: (2021)

The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial
por: Jurgens, M. S., et al.
Publicado: (2020)

Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide
por: Kikuchi, Taku, et al.
Publicado: (2017)

Dexamethasone/prednisone/tocilizumab: Worsening of Strongyloides infection: case report
Publicado: (2020)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including HandScan (Optical Spectral Transmission) Scores
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022)

Prednisone/tocilizumab: Staphylococcus aureus bacteraemia and aortic valve endocarditis : case report
Publicado: (2021)

What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis
por: Messelink, Marianne A, et al.
Publicado: (2023)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
por: Gabay, Cem, et al.
Publicado: (2016)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
por: Pappas, Dimitrios A., et al.
Publicado: (2019)

Effectiveness, Cost-effectiveness, and Cost-Utility of a Digital Smoking Cessation Intervention for Cancer Survivors: Health Economic Evaluation and Outcomes of a Pragmatic Randomized Controlled Trial
por: Mujcic, Ajla, et al.
Publicado: (2022)

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
por: Voshaar, Marieke, et al.
Publicado: (2016)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
por: Fautrel, B, et al.
Publicado: (2020)

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review
por: Verhoeven, M. M. A., et al.
Publicado: (2019)

Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review
por: Vincken, Nanette L A, et al.
Publicado: (2022)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
por: Burmester, Gerd R, et al.
Publicado: (2014)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence
por: van Heuckelum, M., et al.
Publicado: (2019)

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies
por: Roodenrijs, Nadia M. T., et al.
Publicado: (2018)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
por: Rak, Mariola B., et al.
Publicado: (2023)

Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis
por: Cuppen, Bart V. J., et al.
Publicado: (2016)

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
por: Best, Jennie H., et al.
Publicado: (2020)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

New antirheumatic effects of biphosphonate treatment
por: Konenkova, L, et al.
Publicado: (2001)

Note on the Action of Malakin as an Antipyretic and Antirheumatic
por: Abernethy, Robert
Publicado: (1895)

The role of antirheumatics in patients with COVID-19
por: Nissen, Christoffer B, et al.
Publicado: (2021)

COVID-19 vaccination and antirheumatic therapy
por: Arnold, Jack, et al.
Publicado: (2021)

Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis
por: Pouw, Juliëtte N., et al.
Publicado: (2022)

Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
por: Bykerk, Vivian P., et al.
Publicado: (2015)

Effectiveness, Cost-effectiveness, and Cost-Utility of a Digital Alcohol Moderation Intervention for Cancer Survivors: Health Economic Evaluation and Outcomes of a Pragmatic Randomized Controlled Trial
por: Mujcic, Ajla, et al.
Publicado: (2022)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_26rubrk9so71t1ll25bh578rhh